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Abstract
Background: To systematically assess the prevalence of BRCA1 and BRCA2 gene mutations in women with
Hereditary Breast and/or Ovarian Cancer (HBOC) in Arab countries and to describe the variability in the BRCA gene
mutations in different regions of the Arab world.
Methods: Observational studies reporting prevalence of BRCA mutations from 22 Arab countries were
systematically searched in databases including PUBMED, EMBASE, Web of Science, and Google Scholar. Two
reviewers independently screened the studies and extracted data and assessed the risk of bias. Hoy’s risk of Bias
tool was used to assess the biases in individual studies. Due to substantial heterogeneity, pooled weighted
estimates were calculated using Quality Effect Models (QEM) that adjust for bias, while the Random Effect Models
(REM) estimates served as the sensitivity estimates.
Results: Fourteen studies reporting prevalence of BRCA were included. The pooled estimate of BRCA among HBOC
was 20% (95% CI: 7–36%). Subgroup analysis including only those with low risk of bias provided an estimate of 11%
(95% CI: 1–27%). Levant region had higher prevalence 28% (95% CI: 11–49%) compared to Arabian Gulf region and
North Africa but differences are not statistically significant, when tested using Z-test for proportions.
Conclusion: Given the pooled estimates vary widely with substantial heterogeneity, larger, well-designed studies
are warranted to better understand the frequency and the impact of BRCA gene mutations among Arab women.
Trial registration: International Prospective Register of Systematic Reviews (PROSPERO) registration number:
CRD42018095905.
Keywords: BRCA mutations, Familial breast cancer, Familial ovarian cancer, Arab countries, Systematic review, meta-
analysis
Background
Hereditary Breast and/or Ovarian cancer (HBOC) is an
autosomal dominant cancer, that produce higher than
normal levels of breast cancer and ovarian cancer in
genetically related families [1]. About 5–10% of all breast
cancer cases [2] and more than 23% of all ovarian can-
cers [3] are thought to be hereditary. BRCA genes have
been identified to be the most commonly linked germ
line mutations [4]. Harmful mutations in the BRCA1
and BRCA2 genes can produce very high rates of breast
and ovarian cancer and increases the risk of developing
breast cancer by up to 85% and the ovarian cancer by up
to 54% [3].
However, BRCA frequencies are known to vary be-
tween populations. For instance, the prevalence of
BRCA1 in Japan were reported to be as low as 2.6%
while in the USA it can be as high as 11.1% [30]. Under-
standing population specific BRCA gene distributions
can be helpful in developing appropriate risk assessment
strategies that can help reduce the risk of developing
cancers. It is also important in developing cost-effective
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strategies for genetic testing for BRCA mutations [5]. In
terms of prognosis breast or/and ovarian cancer patients
with family history of the disease with one or more of
family members differs from sporadic cancers that occur
without any hereditary link [6].
However, there is paucity of high quality data on the
epidemiology of BRCA mutations in Arab populations,
despite the fact that the breast cancer is the leading
cause of all cancer deaths among Arab women [36]. The
breast cancer also accounts for about 14 to 42% of all fe-
male cancers in the Arab world [37]. For instance, in
Lebanon the breast cancer is leading in cancer inci-
dences, with about 37.6% of all new female cancer cases
diagnosed during the period of 2004–2010 [38]. A study
in Yemen showed that breast cancer accounted 22%
from all cancers cases [39]. Similar incidences were re-
ported from Oman, where the breast cancer accounts
for 25% of all cancer cases [40]. Given that breast cancer
is the most commonly diagnosed cancer among Arab
women [7], understanding the genetic role can help deal
with the diseases better. Moreover, breast and ovarian
cancer patients (BOC) are also diagnosed as early onset
cases in the Arab countries. This led some to suggest
that there exist variant mutations of BRCA genes among
Arabs [8].
To the best of our knowledge, there is no aggregated
data on BRCA gene distribution among Arab women.
To this effect, we aimed to quantify the prevalence of
BRCA1 and BRAC2 gene mutations and to explore the
geographic variability of these gene mutations within the
Arab world. Given the clinical implications in terms of
diagnosis, risk stratifications, and management of breast
or/and ovarian cancer, quantifying the extent to which
these gene mutations prevail in the Arab populations
can be highly valuable.
Methods
Protocol and registration
This present study was conducted following the recom-
mendations provided by the PRISMA [9] and MOOSE
guidelines [10]. This study was registered with the Inter-
national Prospective Register of Systematic Reviews
(PROSPERO) and the registration number is:
CRD42018095905.
Inclusion and exclusion criteria
The following inclusion criteria were used to identify eli-
gible studies: peer reviewed studies published in English
or Arabic; cohort studies, cross-sectional, case-series or
registry based studies, providing sufficient data to com-
pute the prevalence of either BRCA1 or BRCA2 gene
mutations in the breast and / or ovarian cancer patients
in the Arab world.
Studies were excluded if they were confined mainly to
the carriers of BRCA mutations without including other
cancer patients. Those studies that has no information
on family history of disease were also excluded as there
is no way of quantifying HBOC. Likewise, experimental
studies that were evaluating the effect of an intervention
on HBOC patients were also excluded as computing
prevalence in these studies were not possible. Addition-
ally, studies reporting on BRCA1/2 genes mutations in
cancers other than breast or ovarian cancers were also
excluded.
Information sources and databases
The electronic databases Web of Science, PubMed/Med-
line and EMBASE were searched to identify the primary
studies up to April 11, 2018. Further search included
Google Scholar search to identify any relevant studies as
well hand search of the reference lists of the relevant ar-
ticles. Although, there were no systematic reviews or
meta-analyses from this region, we searched for all re-
view articles reporting on the BRCA mutations form
other parts of the world to identify any relevant studies
from Arab countries. Only those published in English
and Arabic were included, and the duplicates studies
were removed using EndNote software.
Search strategy
Studies from all 22 Arab member states of the Arab
league [11] were included. We used the following terms
to be in the “Titles” or “Abstracts: [BRCA],” and
[“Arabs,” or “Qatar,” or “Kuwait,” “Oman,” or “Iraq,” or
“Saudi Arabia,” or “Bahrain,” or “United Arab Emirates,”
or “Yamen,” “Syria,” or “Lebanon,” or “Jordan,” or
“Palestine,” or “Jerusalem,” or “Gaza,” or “Egypt,” or
“Libya,” or “Sudan,” or “Tunisia,” or “Morocco,” or
“Algeria,” or “Somalia,” or “Comoros,” or “Djibouti,” or
“Mauritania.”] and any other variant names for any of
these countries.
Study selection
Two review authors independently assessed titles and
abstracts of all citations retrieved by the search for rele-
vance against the inclusion criteria. Then the full-text
versions of studies considered potentially eligible were
retrieved. The same two authors independently assessed
the full papers for eligibility, with disagreements resolved
through input by a third author [12]. When the eligibil-
ity of a study was unclear, we attempted to contact study
authors.
Data extraction
Two authors independently extracted data from eligible
studies and cross-checked for accuracy and agreement by
the third author. Data extraction using a standardized form
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included variables such as author, year of publication, coun-
try, city, study design, type of disease (BC/OC), age at diag-
nosis, mutation type, mutation test used, overall sample
size and sample size of HBOC subset patients (Table 1).
Methodological quality assessment
We used the risk of bias assessment tool developed by
Hoy et al. [13] to evaluate the quality of individual stud-
ies. The tool has 10 items: four items were related to
Table 1 Characteristics of Studies Included



















– Cross-sectional HBC 41.9 Deleterious PCR2, CS3/
SS4, and TCS5
818 60
Bujassoum 2017 Qatar – Retroa HBC 23–68 Deleterious MLPA6 82 82
Cherbal 2015 Algeria High Plains Cross-sectional HBOCc < 50 Deleterious
VUS
PCR2 192 192
El Saghir 2015 Lebanon Beirut Cross-sectional HBC 40.8 Deleterious
VUS
MLPA6 250 74
Ibrahim 2010 Egypt Alexandria Registry data HBC 43.5 Deleterious SSCP7
HAC8
60 39


















Laraqui 2013 Morocco Rabat Retro HBC – Deleterious DS14 121 19









Tazzite 2012 Morocco Casablanca Case series HBOC 25–60 Deleterious DS15 40 34




aRetro: retrospective cohort study
bHBC: hereditary breast cancer
cHBOC: hereditary breast and/or ovarian cancer
1BART: Comprehensive BRACAnalysis and BRACAnalysis rearrangement test
2PCR: Polymerase chain reaction
3CS: Capture sequencing
4SS: Sanger sequencing
5TCS: Targeted capture sequencing
6MLPA: Multiple ligation dependent probe amplification
7SSCP: single strand conformation polymorphism assay
8HAC: Heteroduplex assay confirmation
9Fluorescent direct sequencing of the entire coding region and intronic sequence flanking each exon
10DHPLC: denaturing high performance liquid chromatography
11CSS: Conventional individual exon-by-exon Sanger sequencing
12NGS: Next generation sequencing
13TS: Target screening for exon 10 in BRCA2
14Direct sequencing of all coding exons and flanking intron sequences of the BRCA1 gene
15DS: Direct Sequencing
16Direct sequencing
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external validity in terms of how well study sample rep-
resent the study population and remaining six items
were related to internal validity of the studies. Total
quality scores for each study was obtained by summing
the binary response scores (Yes = 1 or No =0) that
ranged from 0 to 10. As per Hoy et al. [13], scores above
7 indicated low risk of bias while a score between 6 to 7
indicated moderate risk of bias. Those studies scoring
less than 6 were considered to have high risk of bias.
Syntheses of results
We pooled the quantitative data using Meta-XL version
5.3 [14]. We reported the pooled prevalence and 95%
confidence intervals (CI) and explored the robustness of
meta-analyses using appropriate meta-analytical models
based on the level of heterogeneity. Statistical heterogen-
eity were assessed using Cochrane Q statistic and
I-squared (I2) statistics [15].
In the absence of heterogeneity, the Fixed Effect
Models (FEM) were used. When substantial heterogen-
eity is encountered, the Quality Effects Models (QEM)
were used to pool the prevalence [16]. Significant
heterogeneity is indicated by a significant P-value of the
Cochrane-Q test or an I2 statistic value that is higher
50%. We used the quality scores computed by ROB as-
sessment tool to fit the bias adjusted QEM. Additionally,
Random Effect Models (REM) were used to obtain
sensitivity estimates when substantial heterogeneity is
encountered. We further investigated the sources of
heterogeneity using subgroup analysis. We used a-priori
defined test to compare the pooled prevalence in three
different regions of the Arab world: Levant, North Africa
and Arabian Gulf Co-operation Countries (GCC) using
Z- tests for proportions.
Results
Selection of studies
The database search generated a total of 6315 records
(Fig. 1). We excluded 6249 studies and reasons for ex-
clusions are listed in the Fig. 1. We assessed the full text
of 66 studies for their eligibility. Three authors inde-
pendently read through the full texts and identified
those eligible for the review based on a-priori inclusion
criteria. Only 14 publications were found to be eligible
and included in this study.
Fig. 1 Flowchart representing the process of screening and selection of eligible studies, based on Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines
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Study characteristics
The 14 studies selected were all peer reviewed full length
publications form nine different Arab countries. All
these 14 articles were published in English and published
during the period of 2007 and 2018. They reported on
the prevalence of BRCA1 and / or BRCA2 mutations
among breast or/ and ovarian cancer patients. Of these,
eight were conducted in North African countries, four
from Levant, and two from GCC. There were three stud-
ies from Morocco: one each from North-east Morocco
[27], Casablanca [22] and Rabat [4]. Two studies each
from the following countries. Algeria [23, 25], Lebanon
[7, 26], and Tunisia [20, 21]. Single studies from each of
the following countries: Qatar [17], Saudi Arabia [5],
Jordan [24], Palestine [19], and Egypt [18].
Sample sizes of the included studies ranged between10 to
192, and total number of patients pooled was 917. Of these,
11 studies included Hereditary Breast Cancer (HBC)
patients, three had Hereditary Breast and/or Ovarian
Cancer (HBOC) patients, and a single study included only
Heredity Ovarian Cancer (HOC) patients. Seven studies
investigated both BRCA1 and BRCA2 gene mutations, six
studies had data on only BRCA1 gene mutation and one
study was exclusively on BRCA2 mutations. There were
variation in the methods used to detect BRCA mutations.
Three studies used direct sequencing, while others used
varying types of methods.
Risk of Bias
Of the 14 articles included in our study, eight studies were
found to have moderate risk of bias [4, 17–23], and six
had lower risk of bias [5, 7, 24–27]. In term of the external
validity components, only three articles were considered
to have a good external validity [5, 25, 27] (See Fig. 2).
Quantitative synthesis
From studies reported total BRCA mutation cases, the
overall pooled prevalence of BRCA among breast and/or
Fig. 2 Risk of bias plot that shows the methodological quality assessment of the 14 studies included
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ovarian cancer based on QEM was 20% (95% CI: 7–36%)
[4, 5, 7, 17–27] (Fig. 3a). The pooled prevalence of
BRCA1 mutation among hereditary breast and/ or
ovarian cancer was 12% (95% CI: 4–21%) (Fig. 3b) [4, 5,
7, 17, 19–25]. The estimated pooled prevalence of
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Fig. 3 a Pooled prevalence of any BRCA mutations among hereditary population obtained using Quality Effect Model (QEM). b Pooled
prevalence of BRCA1 mutations among hereditary sample obtained using Quality Effect Model (QEM). c Pooled prevalence of BRCA2 mutations
among hereditary sample obtained using Quality Effect Model (QEM)
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reported such mutation in the HBOC population [7, 17,
21, 22, 27] (Fig. 3c). Further, six studies reported preva-
lence of BRCA mutation among non- hereditary sample
[4, 5, 7, 18, 22, 23]. The pooled prevalence in this popu-
lation was estimated to be 10% (95% CI: 0–28%).
Of all 14 studies included, 13 reported prevalence of
BRCA among breast cancer patients and the pooled
prevalence was 21% (95% CI: 6–40%) [4, 5, 7, 17, 19–
26]. Of this, the prevalence of BRCA1 mutation alone
among breast cancer patients was 11% (95% CI: 4–21%)
[4, 5, 7, 17, 19–25]. Likewise, the prevalence of BRCA2
mutations among breast cancer patients was 17% (95%
CI: 9–27%) [7, 17, 21, 22, 24]. Only one study reported
the prevalence of BRCA1 mutations among ovarian can-
cer patients which was in Algeria [25] with a prevalence
of 1% (95% CI: 0–2%).Three studies [17, 22, 27] out of
14 studies report a prevalence of BRCA1 or BRCA2
among both Breast and Ovarian Cancer patients, the
pooled prevalence was 9% (95% CI: 0–25%).
All the estimates provided above are QEM based to
adjust for bias in individual studies. However, the Ran-
dom Effect Model (REM) is a commonly used and is
recommended by Cochrane group as the choice of
model when there is substantial heterogeneity between
studies included in a meta-analysis [12]. We therefore
used REM as a sensitivity method to compare the QEM
estimates. Table 2 shows a comparison between QEM
and REM estimates, which were not much different.
We repeated the primary analysis of overall pooled
prevalence of BRCA among hereditary breast or/and
Table 2 Comparison between Quality Effect Model and the Random Effect Model results










All eligible studies 14 (917) 20% (7–36%) 94.6% 14 (917) 63% (17–44%) 94.6%
Risk of Bias
Low ROB 6 (604) 11% (1–27%) 94.7% 6 (604) 66% (4–31%) 94.7%
Moderate ROB 8 (313) 40% (21–60%) 87.1% 2 (313) 63% (26–59%) 87.1%
Studies with good
external validity




7 (477) 34% (18–52%) 93.2% 7 (477) 78% (22–56%) 93.2%
BRCA1 11 (684) 19% (7–36%) 92.8% 11 (684) 59% (15–42%) 92.8%
BRCA2 6 (488) 27% (16–40%) 87.4% 6 (488) 75% (18–42%) 87.4%
Target population
HBOC 3 (348) 7% (0–20%) 91.8% 3 (348) 55% (0–25%) 91.8%
HBC 11 (569) 32% (18–47%) 90.8% 10 (550) 65% (23–50%) 90.8%
HOC 1 (192) 2% (0–5%) 0 1 (192) 33% (0–5%) 0
Geographic Location
Levant 4 (240) 28% (11–49%) 87.9% 4 (240) 63% (13–49%) 87.9%
GCC 2 (142) 22% (0–58%) 93.9% 2 (142) 24% (0–56%) 93.9%
North Africa 8 (535) 16% (0–43%) 96.2% 8 (535) 64% (11–54%) 96.2%
Sample size
< 100 12 (603) 29% (16–44%) 89.9% 12 (603) 62% (21–48%) 89.9%
≥100 2 (314) 5% (0–16%) 91.4% 2 (314) 52% (0–17%) 91.4%
Year of recruitment
≤2011 10 (467) 25% (8–47%) 93.1% 10 (467) 60% (17–52%) 93.1%
2012–2018 5 (572) 13% (1–31%) 95.6% 5 (572) 71% (5–37%) 95.6%
Type of mutation
Deleterious 8 (532) 26% (11–44%) 93.6% 8 (532) 71% (17–49%) 93.6%
Deleterious and VUS 2 (266) 10% (0–100%) 98.8% 2 (266) 73% (0–85%) 98.8%
Deleterious, VUS,
and Polymorphisims
4 (119) 20% (4–43%) 72.4% 4 (119) 46% (7–57%) 85.0%
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ovarian cancer by only including the low risk of bias
studies to estimate the prevalence of high quality studies
[5, 7, 24–27]. The pooled prevalence of BRCA mutations
among the high quality studies were estimated to be
11% (95CI: 1–27%). This compared to the overall pooled
prevalence including all studies was lower and much
more comparable with the global estimates.
Quality effect model (QEM) used for subgroup ana-
lysis from different geographical locations in GCC,
Levant and North Africa to understand any geographic
variations in the prevalence of BRCA mutations among
hereditary breast or/and ovarian cancer patients. The
highest pooled prevalence of BRCA mutations was esti-
mated in Levant region the pooled prevalence was 28%
(95% CI: 11–49%) followed by the Gulf region where the
pooled prevalence was 22% (95% CI: 0–58%). Compar-
able prevalence in the North African region was lower
than other regions, as it was estimated to be 16%
(95%CI: 0–44%). These estimates did not differ statisti-
cally based on Z- test for proportions.
Heterogeneity assessment
Significant heterogeneity was encountered throughout
the analysis as indicated by the p values of the Cochrane
Q statistics and I2 statistics values. For instance, the
studies [4, 5, 7, 17–27] included to pool the prevalence
for BRCA mutations had a Cochran Chi-square p value
of < 0.001 and I2 of 95%. Likewise, there were significant
heterogeneity across the studies used to obtain the























































Fig. 4 a Funnel plot assessing the publication bias in pooling the prevalence of any BRCA mutation. b Funnel plot assessing the publication bias
in pooling the prevalence of BRCA1 mutation. c. Funnel plot assessing the publication bias in pooling the prevalence of BRCA2 mutation
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(Chi-square = 69.2, p-value< 0.001, I2 = 86%) [4, 5, 7, 17,
19–25]. For BRCA2 heterogeneity between the studies
were also substantial (Chi-square = 23.5, p-value < 0.001,
I2 = 79.7%) [7, 17, 21, 22, 27].
For total BRCA mutations among general population,
there was a considerable heterogeneity across studies
(Chi-square = 70, P value = 0.001, I- square = 94.3%) and
the pooled prevalence was 35% (95% %CI: 16–55%). The
pooled prevalence of BRCA1 mutation among Breast
Cancer Patients was 11% (95% CI: 4–21%) [4, 5, 7, 17,
19–25], and there was a substantial heterogeneity across
the studies (Chi-square = 79.3, P value < 0.001, I-square
= 87.38%). As for the prevalence of BRCA 2 mutation
among Breast Cancer patients, data was reported from 5
studies [7, 17, 21, 22, 24]. Where the pooled prevalence
was 17% (95% CI: 9–27%), and significant heterogeneity
was found (Chi-square = 18.5, P value = 0.001, I square =
78.39%). Only one study [25] reported BRCA1 among
ovarian cancer and no studies reported BRCA2 among
ovarian cancer patients, so heterogeneity was not
assessed. For BRCA1 or/and BRCA2 among patients
with both Breast and Ovarian cancer, the pooled preva-
lence was 9% (95% CI: 0–25%) [17, 22, 27]. For hetero-
geneity, there was large heterogeneity detected
(Chi-square = 19, P value < 0.001, I-square = 89.4%).
Publication Bias
Publication bias was investigated using classical funnel
plot, where an asymmetry indicated potential publication
bias (Fig. 4a, b and c). As for BRCA1 and BRCA2 muta-
tions estimates in hereditary patients, funnel plots
showed a potential publication bias. However, Hunter et
al. [28] suggested that conventional funnel plots, that as-
sess publication bias, are inaccurate for prevalence
meta-analysis. We are unsure about the asymmetry ob-
served in our study if it is true reflection of publication
bias or simply an over-estimate as argued by Hunter et
al. [28].
Discussion
This study included 14 eligible studies from nine Arab
countries, to systematically review the prevalence of
BRCA mutations. The study revealed that one in five
hereditary breast or/and ovarian cancer patients in the
Arab region are likely to have BRCA mutations. The
prevalence BRCA2 were more common (17%) than
BRCA1 mutations (11%) in the region. The prevalence
of BRCA mutations were also noted to vary considerably
from other populations [31–35]. For instance, prevalence
of BRCA gene mutations in India, Japan, Hispanics in
USA, and Spain were substantially higher than that of
the Arab populations, whilst Iran, Mexico, Sweden,
Germany, Australia and Turkey reported significantly
lower prevalence (Table 3).
There were variability in the prevalence of BRCA
mutations between different areas of the Arab region.
Such differences might be explained by biological dif-
ferences in the BRCA gene prevalence [23], varying
age at onset in the study population with varying pro-
portion of younger population in different parts of
the Arab world. This was further amplified by the
fact that the diagnosis at a young age is an indication
for the referral for BRCA testing. Studies have also
suggested that there is a variation of BRCA preva-
lence among different ethnicities [41], while others
found that the prevalence of BRCA mutations is the
same across different ethnicities [42]. Family history
of breast or ovarian cancer could be a significantly
strong predictor for being a carrier of BRCA gene
mutations [43] as this could be another reason for
having a variation in the prevalence of mutations.
Table 3 Comparison between the pooled prevalence in Arab countries with other regions around the world
Author (year) Country Sample size BRCA mutation
prevalence
z-score P-value
Keshavarzi et al. (2011) Iran 85 7% 15.429 < 0.0001
Vaca-Panigua et al. (2012) Mexico 39 7.7% 13.97 < 0.0001
Loman et al. (2001) Sweden 234 8.9% 11.81 < 0.0001
Hamann et al. (2003) Germany 23 13% 6.30 < 0.0001
Alsop et al. (2012) Australia 1001 14.1% 5.134 < 0.0001
Yazici et al. (2000) Turkey 53 15.1% 4.144 < 0.0001
Sharma et al., (2014) Kansas, USA 207 15.4% 3.86 0.0001
Han et al. (2013) Korea 775 21.7% 1.25 0.2117
Hedau et al. (2004) India 24 25% 3.497 = 0.0005
Sugano et al. (2008) Japan 135 26.7% 4.59 < 0.0001
Weitzel et al. (2005) Hispanics in USA 110 30.9% 7.14 < 0.0001
Hoya et al. (2001) Spain 102 43% 14.07 < 0.0001
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Our findings have important clinical implications.
Firstly, the previously held notion that Arab population
has less frequent BRCA mutations compared to other
regions of the world [7] may not be entirely true. It is
also possible that the BRCA mutations may be linked to
the increases in the breast and ovarian cancer cases in
Arab countries [29] along with other reasons such as
weaker screening programs [44]. Increasing incidences
in the breast and ovarian cancer cases in the region
could also be associated with having children at older
age, increased use of oral contraceptives and reduced
breastfeeding as well as increasing level of obesity and
physical inactivity [45, 46]. Appropriate risk assessment
strategies may help manage and control the risk of
breast and ovarian cancer, targeted particularly in the
region with higher BRCA mutations [5].
Our study has some limitations. There were paucity
of data on BRCA mutations in most part of the Arab
world. All of the 14 studies included in this paper
came from nine countries and the rest of the 14
countries had no published reports on BRCA preva-
lence. As for the quality of studies included, most of
them had moderate to lower risk of bias, but with
higher risk of external validity. This indicates that the
studies may not have been well representative of the
respective study populations from where these reports
originated. There were also substantial heterogeneity
among the studies, that presented a major threat to
the validity of the pooled estimates. High quality
epidemiological studies in Arab populations are, thus
warranted.
Conclusion
We conclude that one in five HBOC patients in the
Arab world have BRCA mutations. The BRCA2 is the
most prevalent type mutation among breast cancer
patients in the Arab region, with an estimated preva-
lence was 17% with a higher pooled prevalence of BRCA
mutations in the Levant Region 28%. When we com-
pared with studies from different parts of the world the
Arab world appear to have different profiles with varying
BRCA frequencies. High quality epidemiologic studies
are warranted to understand the impact of the BRCA
gene mutations and their role in breast and ovarian can-
cer incidence, risk and prognosis in the Arab world that
is experiencing a steady increase in the cancer incidence.
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